Evidence map›Paper›PMID 34895172›Full record

ArticleBMC medical research methodology2021

Moving beyond the classic difference-in-differences model: a simulation study comparing statistical methods for estimating effectiveness of state-level policies.

Beth Ann Griffin, Megan S Schuler, Elizabeth A Stuart, Stephen Patrick, Elizabeth McNeer, Rosanna Smart, David Powell, Bradley D Stein, Terry L Schell, Rosalie Liccardo Pacula

Erratum issuedAbstract read
In one paragraph

Article in BMC medical research methodology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Target Trial Emulation for Evaluating Health Policy.Annals of internal medicine · 2024
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Beth Ann GriffinRAND Corporation, 1200 South Hayes Street, Arlington, VA, 22202, USA. bethg@rand.org.
Megan S SchulerRAND Corporation, 1200 South Hayes Street, Arlington, VA, 22202, USA.
Elizabeth A StuartJohns Hopkins Bloomberg School of Public Health, Baltimore, MD, 21205, USA.
Stephen PatrickVanderbilt University Medical Center and School of Medicine, Nashville, TN, 37232, USA.
Elizabeth McNeerVanderbilt University Medical Center and School of Medicine, Nashville, TN, 37232, USA.
Rosanna SmartRAND Corporation, Santa Monica, CA, 90401, USA.
David PowellRAND Corporation, 1200 South Hayes Street, Arlington, VA, 22202, USA.
Bradley D SteinRAND Corporation, Pittsburgh, PA, 15213, USA.
Terry L SchellRAND Corporation, Santa Monica, CA, 90401, USA.
Rosalie Liccardo PaculaUniversity of Southern California, Los Angeles, CA, 90089, USA.

Funding

Optimal Methods for Estimating Policy Effect Heterogeneity in Opioid Policy ResearchP50DA046351 · NIDA · RAND CORPORATION · PI BRADLEY D STEIN · 2018 to 2026
$20.8M
Scientific and Technical CoreP2CHD041022 · NICHD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Martha Jane Bailey · 2016 to 2026
$6.9M
NICHD NIH HHS P2C HD041022NIDA NIH HHS P50 DA046351
6 · The paper itself

Abstract

backgroundReliable evaluations of state-level policies are essential for identifying effective policies and informing policymakers' decisions. State-level policy evaluations commonly use a difference-in-differences (DID) study design; yet within this framework, statistical model specification varies notably across studies. More guidance is needed about which set of statistical models perform best when estimating how state-level policies affect outcomes.

methodsMotivated by applied state-level opioid policy evaluations, we implemented an extensive simulation study to compare the statistical performance of multiple variations of the two-way fixed effect models traditionally used for DID under a range of simulation conditions. We also explored the performance of autoregressive (AR) and GEE models. We simulated policy effects on annual state-level opioid mortality rates and assessed statistical performance using various metrics, including directional bias, magnitude bias, and root mean squared error. We also reported Type I error rates and the rate of correctly rejecting the null hypothesis (e.g., power), given the prevalence of frequentist null hypothesis significance testing in the applied literature.

resultsMost linear models resulted in minimal bias. However, non-linear models and population-weighted versions of classic linear two-way fixed effect and linear GEE models yielded considerable bias (60 to 160%). Further, root mean square error was minimized by linear AR models when we examined crude mortality rates and by negative binomial models when we examined raw death counts. In the context of frequentist hypothesis testing, many models yielded high Type I error rates and very low rates of correctly rejecting the null hypothesis (< 10%), raising concerns of spurious conclusions about policy effectiveness in the opioid literature. When considering performance across models, the linear AR models were optimal in terms of directional bias, root mean squared error, Type I error, and correct rejection rates.

conclusionsThe findings highlight notable limitations of commonly used statistical models for DID designs, which are widely used in opioid policy studies and in state policy evaluations more broadly. In contrast, the optimal model we identified--the AR model--is rarely used in state policy evaluation. We urge applied researchers to move beyond the classic DID paradigm and adopt use of AR models.

Indexed as

Analgesics, OpioidModels, StatisticalComputer SimulationHumansLinear ModelsPolicyAnalgesics, OpioidDifference-in-differencesOpioidOverdosePolicy evaluationsSimulationState-level policy

Identifiers

PMID34895172
PMCPMC8666265

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.